Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JMJD6 | Q6NYC1 | 3/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.38 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.36 |
| ▸ | PDE4A | P27815 | 3/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.35 |
| ▸ | BRAF | P15056 | 2/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
| ▸ | CETP | P11597 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2316266 | 0.91 | MAPK14 (0.33) | JMJD6MAPK14BRAFPSEN1PSEN2 | |
| SCHEMBL2315864 | 0.91 | PDE10A (0.34) | JMJD6PDE10APDE4APDE4BPDE3B | |
| SCHEMBL2313575 | 0.90 | CSNK1D (0.40) | JMJD6MAPK14CSNK1DCSNK1EMAPK13 | |
| SCHEMBL14719347 | 0.87 | CSNK1D (0.38) | MAPK14CSNK1DCSNK1EMAPK13MAPK12 | |
| SCHEMBL2317765 | 0.87 | PSEN1 (0.35) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL14108519 | 0.87 | CSNK1D (0.36) | JMJD6MAPK14CSNK1DCSNK1EMAPK13 | |
| SCHEMBL2315544 | 0.84 | KDM4E (0.34) | JMJD6BRAFCETPKDM4EMAPT | |
| SCHEMBL2315677 | 0.84 | MAPK14 (0.34) | JMJD6MAPK14PSEN1PSEN2APH1B | |
| SCHEMBL14719565 | 0.84 | MAPK14 (0.35) | JMJD6MAPK14CSNK1DCSNK1EMAPK13 | |
| SCHEMBL2316375 | 0.83 | JMJD6 (0.33) | JMJD6MAPK14BRAFPSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528909-B1 | SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-06-22 | — | — | EP | claimed |
| US-8791265-B2 | Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-07-29 | — | — | US | claimed |
| US-20130053419-A1 | SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | LSI FINANCING 1 DESIGNATED ACTIVITY COMPANY (IE) | 2013-02-28 | — | — | US | claimed |
| EP-2528909-A1 | SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2012-12-05 | — | — | EP | claimed |
| WO-2011092088-A1 | SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-08-04 | — | — | WO | claimed |
| EP-2528909-B1 | SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-06-22 | — | — | EP | disclosed |
| US-8791265-B2 | Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-07-29 | — | — | US | disclosed |
| US-20130053419-A1 | SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | LSI FINANCING 1 DESIGNATED ACTIVITY COMPANY (IE) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053419-A1 | SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | MAP3K15, MAP3K19, CDK3 | JMJD6 1524/4885MAPK14 36/4885CSNK1D 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.